The Prostate Health Podcast

Browse all of the episodes below!

72: Newly Diagnosed with Prostate Cancer – Now What? Simon Kim, MD

72: Newly Diagnosed with Prostate Cancer – Now What? Simon Kim, MD

One of our more popular episodes was with Dr. Simon Kim in Episode 7. For today, we are bringing that episode out of the vault.

Receiving a prostate cancer diagnosis can be a frightening experience that could cause much anguish for men and their loved ones. We are fortunate to have Dr. Simon Kim, a urologic oncologist, as our guest for the show today to walk you through the process. In this episode, Dr. Kim explains what it all means. He discusses the various options and clarifies where to go from there. Stay tuned for more!

Dr. Kim is a board-certified urologic oncologist at the University of Colorado’s Anschutz Medical Campus. He has worn many hats including Director of Robotic Surgery. Dr. Kim’s clinical practice focuses on the surgical management of prostate, bladder, kidney, testes, adrenal, and penile cancer. He has been independently funded by the NIH to develop decision aids for men diagnosed with localized prostate cancer. He has published more than 180 manuscripts and serves as assistant editor for the Journal of Urology. Be sure to listen in today to get Dr. Kim’s expert advice.

71:  Extending Survival with a New Treatment for Men with Advanced Prostate Cancer – A. Oliver Sartor, MD

71: Extending Survival with a New Treatment for Men with Advanced Prostate Cancer – A. Oliver Sartor, MD

We are happy to have an international expert in the arena of the treatment of advanced prostate cancer joining us today. We are excited to talk to him about a new treatment that is extending the survival of men with advanced prostate cancer.

Dr. Oliver Sartor is an internationally recognized expert in prostate cancer. He is currently the Assistant Dean for Oncology at Tulane University’s School of Medicine, Medical Director of the Tulane Cancer Center, and the Ward Professor for Cancer Research. His medical practice and research have focused on prostate cancer since 1990 when he finished a fellowship at the National Cancer Institute.

70: Bladder Cancer Episode: Bladder-Preserving Trimodality Therapy as an Alternative To Radical Cystectomy – Abhishek Solanki, MD, MS

70: Bladder Cancer Episode: Bladder-Preserving Trimodality Therapy as an Alternative To Radical Cystectomy – Abhishek Solanki, MD, MS

Although the primary focus of this podcast is prostate health, we will occasionally break from that topic to cover other important subjects related to urology. Today, we have a special bonus episode about bladder cancer.

We are happy to have Dr. Abhi Solanki joining us on the podcast today! Dr. Solanki is a Radiation Oncologist. After completing his residency training in Radiation Oncology at the University of Chicago Pritzker School of Medicine, he joined the faculty at Loyola University Medical Center, where he is currently an Associate Professor in the Department of Radiation Oncology. He also serves as Quality Medical Director in the department and the Chair of the Genitourinary Cancer Disease Committee at the Cancer Center at Loyola. Much of his clinical focus includes treating genitourinary cancers, including prostate, bladder, kidney, and testicular cancer.

In this episode, we review some of the basics of bladder cancer. We then get you up to speed with all you need to know about bladder-preserving Trimodality Therapy as an alternative to radical bladder removal for muscle-invasive bladder cancer. Stay tuned for more!

69: PARP-Inhibitors: Entering a New Era of Personalized Treatment for Advanced Prostate Cancer – Emmanuel Antonarakis, MD

69: PARP-Inhibitors: Entering a New Era of Personalized Treatment for Advanced Prostate Cancer – Emmanuel Antonarakis, MD

There is a continuous explosion of new and innovative therapies for men with advanced prostate cancer. Recently, two different PARP-Inhibitors were approved by the FDA for use. Those drugs were the first in their class to have been approved as personalized therapy for certain individuals with advanced prostate cancer.

Today, we have Dr. Emmanuel Antonarakis, a world-class expert in the area of targeted therapy for prostate cancer, joining us to talk about the two new medications and explain who might be eligible for that kind of therapy. Be sure to stay tuned for more!

Better Prostate Education is our Mission!

Subscribe to the show on any of these podcast apps

iTunes

Spotify

iHeart Radio